Similar Items: Six‐month real‐world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia
- Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial
- Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience
- Identification of patients receiving amyloid‐targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS
- Regional amyloid PET asymmetry and long‐term clinical trajectory in mild cognitive impairment
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- Anti‐amyloid nanobody‐Fc fusion protein drives potent amyloid clearance through microglial recruitment